Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Remitly Global Inc (RELY) vs Zoetis Inc (ZTS) Price & Performance

Remitly Global IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Remitly Global Inc vs Zoetis Inc — how do they compare? Remitly Global Inc trades at $24.1 (market cap $5.26B), while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 5.8× Remitly Global Inc's market cap, and Zoetis Inc pays a 2.88% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.

RELYZTS
Market Cap
$5.26B$30.40B
Sector
TechnologyHealth
52-Week High
$26.92$150.61
52-Week Low
$12.20$71.91
Enterprise Value
$4.62B$37.96B
Dividend Yield
2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Remitly Global Inc

RELY trades at $24.83, down 5.12% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.93 significantly exceeding expectations of $0.12. Revenue growth is accelerating, reaching $1.64 billion in 2025, with net income turning positive at $67.93 million. A recent partnership with Etsy expands its payment provider reach, signaling business expansion. Analyst consensus is overwhelmingly bullish with a $31.17 price target, representing 25.5% upside from current levels.

The outlook for RELY is positive given its strong revenue trajectory, improving profitability, and strategic partnerships. Key opportunities include continued market share gains in digital remittances and new monetization avenues. Risks involve competitive pressures in fintech, reliance on economic conditions affecting remittance volumes, and potential volatility despite institutional backing. The stock's current pullback may offer a entry point, but investors should weigh execution risks against growth potential.

Zoetis Inc

Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.

The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Remitly Global Inc

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

Read more on RELY

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS